Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation

Nanomedicine

Volumn 6, Issue 10, 2011, Pages 1683-1695

  Chalati, T ^a   Horcajada, P ^b   Couvreur, P ^a   Serre, C ^b   Ben Yahia, M ^c   Maurin, G ^c   Gref, R ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ DE VERSAILLES SAINT QUENTIN EN YVELINES   (France)

^c CNRS   (France)

Author keywords

busulfan; cytotoxicity; drug crystallization; drug loading; drug release; iron (III) carboxylate; nanoparticle; NMR; porous MOF

Indexed keywords

AMPHOPHILE; BUSULFAN; IRON DERIVATIVE; METAL ORGANIC FRAMEWORK; NANOPARTICLE;

ARTICLE; CRYSTALLIZATION; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; POROSITY; PRIORITY JOURNAL;

BUSULFAN; CELL LINE; CELL SURVIVAL; DRUG CARRIERS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; ORGANOMETALLIC COMPOUNDS; PHARMACEUTICAL PREPARATIONS; POROSITY;

EID: 82455204064     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.69     Document Type: Article

References (55)

1. Dunn CDR. The chemical and biological properties of busulfan ('Myleran'). Hemat. 2, 101-117 (1974).
2. Galton DAG. Myleran in chronic myeloid leukemia: results of treatment. Lancet 1, 208-213 (1953).
3. Blazar BR, Ramsay NKC, Kersey JH, Krivit W, Arthur DC, Filipovich AH. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Transplantation 39(6), 597-603 (1985).
4. Hartmann O, Benhamou E, Beaujean F et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a Phase II study. J. Clin. Oncol. 4, 1804-1810 (1986). (Pubitemid 17226671)
5. Santos GW. The development of busulfan/cyclophosphamide preparative regimens. Sem. Oncol. 20, 12-16 (1993). (Pubitemid 23239400)
6. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother. Pharmacol. 28(2) 130-134 (1991).
7. Meresse V, Hartmann O, Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 10, 135-141 (1992).
8. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann. Intern. Med. 118, 255-267 (1993). (Pubitemid 23046384)
9. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veino-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother. Pharmacol. 25(1), 55-61 (1989). (Pubitemid 20000799)
10. Bouligand J, Boland I, Valteau-Couanet D et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant. 32, 979-986 (2003). (Pubitemid 37461533)
11. Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk. Lymphoma 22, 395-407 (1996). (Pubitemid 26341005)
12. Hassan M, Ehrsson H. Degradation of busulfan in aqueous solution. J. Pharm. Biomed. Anal. 4, 95-101 (1986). (Pubitemid 16103337)
13. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother. Pharmacol. 37, 401-408 (1996). (Pubitemid 26054548)
14. Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 22, 241-244 (1998). (Pubitemid 28382987)
15. Andersson BS, Kashyap A, Couriel D et al. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient beneft. Biol. Blood Marrow Transplant. 9, 722-724 (2003). (Pubitemid 38145756)
16. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/effcacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 33, 979-987 (2004). (Pubitemid 38744783)
17. Hassan Z, Nilsson C, Hassan M. Liposomal busulfan: bioavailability and effect on bone marrow in mice. Bone Marrow Transplant. 22, 913-918 (1998). (Pubitemid 28499366)
18. Olavarria E, Hassan M, Eades A et al. A Phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 14, 1954-1959 (2000).
19. Layre AM, Gref R, Richard J et al. Nanoencapsulation of a crystalline drug. Int. J. Pharm. 298(2), 323-327 (2005). (Pubitemid 40910736)
20. Layre A, Couvreur P, Chacun H et al. Busulfan loading into poly (alkyl cyanoacrylate) nanoparticles: physico-chemistry and molecular modelling. J. Biomed. Mater. Res. B Appl. Biomater. 79(2), 254-262 (2006). (Pubitemid 44652049)
21. Lay re A, Couvreur P, Chacun H et al. Novel composite core-shell nanoparticles as busulfan carriers. J. Contr. Release 111(3), 271-280 (2006).
22. Lay re A, Couvreur P, Richard J, Requier D, Ghermani N, Gref R. Freeze-drying of composite core-shell nanoparticles. Drug Dev. Ind. Pharm. 32(7), 839-846 (2006). (Pubitemid 44266768)
23. Bouligand J, Couvreur P, Layre AM et al. Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. J. Microencapsul. 24, 715-730 (2007). (Pubitemid 47559910)
24. Ghermani NE, Spasojevic-de Bire A, Bouhmaida N et al. Molecular reactivity of busulfan through its experimental electrostatic properties in the solid state. Pharm. Res. 21, 598-607 (2004). (Pubitemid 38457282)
25. Férey G. Hybrid porous solids: past, present, future. Chem. Soc. Rev. 37, 191-241 (2008).
26. Férey G, Serre C. Large breathing effects in three-dimensional porous hybrid matter: facts, analyses, rules and consequences. Chem. Soc. Rev. 38, 1380-1399 (2009).
27. Horcajada P, Chalati T, Serre C et al. Porous metal-organic-framework nanocarriers as a potential platform for drug delivery and imaging. Nat. Mater. 9, 172-178 (2010).
28. Whitfeld TR, Wang X, Liu L, Jacobson AJ. Metal-organic frameworks based on iron oxide octahedral chains connected by benzenedicarboxylate dianions. Solid State Sci. 7, 1096-1103 (2005). (Pubitemid 41375860)
29. Horcajada P, Surblé S, Serre C et al. Synthesis and catalytic properties of MIL-100 (Fe), an iron(iii) carboxylate with large pores. Chem. Commun. 27, 2820-2822 (2007). (Pubitemid 47035563)
30. Serre C, Mellot-Draznieks C, Surble S, Audebrandy N, Filinchuk Y, Férey G. Role of solvent-host interactions that lead to very large swelling of hybrid frameworks. Science 315, 1828-1831 (2007). (Pubitemid 46580138)
31. Serre C, Millange F, Surblé S, Férey G. A route to the synthesis of trivalent transition-metal porous carboxylates with trimeric secondary building units. Angew. Chem. Int. Ed. 43, 6285-6289 (2004).
32. Surblé S, Serre C, Mellot-Draznieks C, Millange F, Ferey G. A new isoreticular class of metal organic-frameworks with the MIL-88 topology. Chem. Commun. 3, 284-286 (2006).
33. Chalati T, Horcajada P, Gref R, Couvreur P, Serre C. Optimisation of the synthesis of MOF nanoparticles made of fexible porous iron fumarate MIL-88A. J. Mater. Chem. 21, 2220-2227 (2011).
34. Dziobkowski CT, Wrobleski JT, Brown DB. Magnetic properties and Moessbauer spectra of several iron(III)-dicarboxylic acid complexes. Inorg. Chem. 20(3), 671-678 (1981).
35. Horcajada P, Surblé S, Serre C et al. Synthesis and catalytic properties of MIL-100(Fe), an iron(III) carboxylate with large pores. Chem. Commun. 2820-2822 (2007). (Pubitemid 47035563)
36. Llewellyn PL, Horcajada P, Maurin G et al. Complex adsorption of short linear alkanes in the fexible metal-organic-framework MIL-53(Fe). J. Am. Chem. Soc. 131, 13002-13008 (2009).
37. Devic T, Horcajada P, Serre C et al. Functionalization in fexible porous solids: effects on the pore opening and the host-guest interactions. J. Am. Chem. Soc. 132(3), 1127-1136 (2010).
38. Horcajada P, Serre C, Maurin G et al. Flexible porous metal-organic frameworks for a controlled drug delivery. J. Am. Chem. Soc. 130, 6774-6780 (2008). (Pubitemid 351748413)
39. Perdew JP, Wang Y. Accurate and simple analytic representation of the electron-gas correlation energy. Phys. Rev. B 45, 13244-13249 (1992).
40. Hehre WJ, Ditchfeld R, Pople JA. Self-consistent molecular orbital methods. XII. Further extensions of Gaussian type basis sets for use in molecular orbital studies of organic molecules. J. Chem. Phys. 56, 2257-2261 (1972).
41. Feit PW, Rastrup-Andersen N. 4-Methanesulfonyloxybutanol: hydrolysis of busulfan. J. Pharm. Sci. 62, 1007-1008 (1973).
42. Rieter WJ, Taylor KML, An H, Lin W. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J. Am. Chem. Soc. 128, 9024-9025 (2006). (Pubitemid 44078972)
43. Taylor KML, Jin A, Lin W. Surfactant-assisted synthesis of nanoscale gadolinium metal-organic frameworks for potential multimodal imaging. Angew. Chem. Int. Ed. 47, 7722-7725 (2008).
44. Taylor KML, Rieter WJ, Lin W. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. J. Am. Chem. Soc. 130, 14358-14359 (2008).
45. Demessence A, Horcajada P, Serre C et al. Elaboration and properties of hierarchically structured optical thin flms of MIL-101(Cr). Chem. Commun. 14(46), 7149-7151 (2009).
46. Cravillon J, Munzer S, Lohmeier SJ, Feldhoff A, Huber K, Wiebcke M. Rapid room-temperature synthesis and characterization of nanocrystals of a prototypical zeolitic imidazolate framework. Chem. Mater. 21(8), 1410-1412 (2009).
47. Hermes S, Witte T, Hikov T et al. Trapping metal-organic framework nanocrystals: an in-situ time-resolved light scattering study on the crystal growth of MOF-5 in solution. J. Am. Chem. Soc. 129(17), 5324-5325 (2007). (Pubitemid 46697596)
48. Qiu LG, Li ZQ, Wu Y, Wang W, Xu T, Jiang X. Facile synthesis of nanocrystals of a microporous metal-organic framework by an ultrasonic method and selective sensing of organoamines. Chem. Comm. 31, 3642-3644 (2008).
49. Li ZQ, Qiu LG, Su T et al. Ultrasonic synthesis of the microporous metal-organic framework Cu3(BTC)2 at ambient temperature and pressure: an effcient and environmentally friendly method. Mater. Lett. 63(1), 78-80 (2009).
50. Horcajada P, Serre C, Grosso D et al. Colloidal route for preparing optical thin flms of nanoporous metal-organic frameworks. Adv. Mater. 21, 1931-1935 (2009).
51. Vallet-Reghi M, Colilla M, Gonzalez B. Medical applications of organic-inorganic hybrid materials within the feld of silica-based bioceramics. Chem. Soc. Rev. 40, 596-607 (2011).
52. Sheftel VO. Indirect Food Additives and Polymers: Migration and Toxicology. Ministry of Health, (Lewis Publishers Inc.) Jerusalem, Israel, 148-154 (2000).
53. Goyer RA. Toxic effects of metals. In: Casarett & Doull's Toxicology. The Basic Science of Poisons. Klaassen CD (Ed.). McGraw-Hill Health professions division, NY, USA (1996).
54. Klibanov AL, Maruyama K, Torchilin V P, Huang L. Amphiphatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235-237 (1990). (Pubitemid 20233874)
55. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long circulating polymeric nanospheres. Science 263, 1600-1603 (1994). (Pubitemid 24128361)